Patents by Inventor John G. Curd

John G. Curd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20180264107
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Applicants: Genentech, Inc., Biogen Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez, Lori A. Kunkel
  • Treatment of pemphigus
    Patent number: 9993550
    Abstract: The present invention concerns treatment of pemphigus with an antibody which binds to CD20.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 12, 2018
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • TREATMENT OF PEMPHIGUS
    Publication number: 20160175435
    Abstract: The present invention concerns treatment of pemphigus with an antibody which binds to CD20.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 23, 2016
    Applicants: BIOGEN INC., GENENTECH, INC.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • ADMINISTRATION OF GLUFOSFAMIDE FOR THE TREATMENT OF CANCER
    Publication number: 20160143929
    Abstract: Administration of Glufosfamide alone and in combination with another anticancer agent is useful for the treatment of gall bladder cancer.
    Type: Application
    Filed: January 29, 2016
    Publication date: May 26, 2016
    Inventor: John G. Curd
  • TREATMENT OF CANCER USING HYPOXIA ACTIVATED PRODRUGS
    Publication number: 20150258125
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anticancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Application
    Filed: December 17, 2014
    Publication date: September 17, 2015
    Inventors: John G. Curd, Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Jessica D. Sun
  • Treatment of hyperproliferative diseases with vinca alkaloid N-oxide analogs
    Patent number: 8883775
    Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: November 11, 2014
    Assignee: Cascade Prodrug Inc.
    Inventors: John G. Curd, John F. W. Keana, Alshad S. Lalani, Paul B. Westberg, Bradford Goodwin, W. David Henner
  • TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20140134164
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicants: BIOGEN IDEC INC., GENENTECH, INC.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • TREATMENT OF PEMPHIGUS
    Publication number: 20130330332
    Abstract: The present invention concerns treatment of pemphigus with an antibody which binds to CD20.
    Type: Application
    Filed: August 16, 2013
    Publication date: December 12, 2013
    Applicants: Biogen Idec Inc., Genentech, Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20130273042
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: June 11, 2013
    Publication date: October 17, 2013
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of vasculitis
    Patent number: 8545843
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 1, 2013
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20120201818
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
    Patent number: 8206711
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: June 26, 2012
    Assignees: Biogen Idec Inc., Genentech, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
  • Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide Analogs
    Publication number: 20120107230
    Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
    Type: Application
    Filed: October 25, 2011
    Publication date: May 3, 2012
    Applicants: UNIVERSITY OF OREGON
    Inventors: JOHN G. CURD, JOHN F.W. KEANA, ALSHAD S. LALANI, PAUL B. WESTBERG, BRADFORD GOODWIN, W. DAVID HENNER
  • Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs
    Patent number: 8048872
    Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: November 1, 2011
    Assignee: Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon
    Inventors: John G. Curd, John F. W. Keana, Alshad S. Lalani, Paul B. Westberg, Bradford Goodwin, W. David Henner
  • Administration of Glufosfamide For The Treatment of Cancer
    Publication number: 20110207680
    Abstract: Administration of Glufosfamide alone and in combination with another anticancer agent is useful for the treatment of gall bladder cancer.
    Type: Application
    Filed: July 31, 2009
    Publication date: August 25, 2011
    Inventor: John G. Curd
  • Treatment of Autoimmune Diseases
    Publication number: 20110008338
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Autoimmune Diseases
    Publication number: 20110008337
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genetech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Autoimmune Diseases
    Publication number: 20110008336
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Autoimmune Diseases
    Publication number: 20110008250
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of autoimmune diseases
    Patent number: 7820161
    Abstract: Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 26, 2010
    Assignees: Biogen Idec, Inc., Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez